(Q35156061)

6 August 2017

1 reference

title

Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches (English)

1 reference

6 August 2017

1 reference

1 reference

Samira Syed

1

1 reference

6 August 2017

Daniel P Petrylak

series ordinal

2

1 reference

6 August 2017

Ian M Thompson

series ordinal

3

1 reference

6 August 2017

publication date

1 May 2003

1 reference

6 August 2017

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

235-243

1 reference

The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974-1993.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Analysis of recent trends in prostate cancer incidence and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Follow-up prostate cancer treatments after radical prostatectomy: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Indicators of pathologic stage of prostate cancer and their use in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Radical perineal prostatectomy: oncological outcome during a 20-year period.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Ability of sextant biopsies to predict radical prostatectomy stage

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Pathologic classification of prostate carcinoma: the impact of margin status

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Disease progression following radical prostatectomy in men with Gleason score 7 tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Adjuvant therapy of colon cancer: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Adjuvant therapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Evaluation of adjuvant estramustine phosphate, cyclophosphamide, and observation only for node-positive patients following radical prostatectomy and definitive irradiation. Investigators of the National Prostate Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Adjuvant mitozantrone chemotherapy in advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Neoadjuvant estramustine and etoposide followed by concurrent estramustine and definitive radiotherapy for locally advanced prostate cancer: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

The role of adjuvant irradiation following primary prostatectomy, based on histopathologic extent of tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

An opportunity to determine optimal treatment of pT3 prostate cancer: the window may be closing

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Tr

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Hormonal treatment before radical prostatectomy: a 3-year followup

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Neoadjuvant hormonal therapy: the Canadian experience

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule.

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Adjuvant radiotherapy following radical prostatectomy: results and complications

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Radiation therapy as adjuvant treatment after radical prostatectomy: patient tolerance and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Update on impact of moderate dose of adjuvant radiation on urinary continence and sexual potency in prostate cancer patients treated with nerve-sparing prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Adjuvant radiation therapy in stages C and D1 prostatic adenocarcinoma: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Postoperative radiation therapy for pathologic stage C prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2803%2900033-4

7 January 2021

10.1016/S1078-1439(03)00033-4

Identifiers

DOI

1 reference

6 August 2017

1 reference